Fig. 5

Chidamide and anlotinib synergistically suppressed the PI3K/AKT cascade in vivo by inhibiting HDAC3 and VEGFR2 respectively. (a) Chidamide combined with anlotinib synergistically inhibited HDAC3 and VEGFR2 expression in vivo. Tumor slices were immunohistochemically incubated with HDAC3 (upper row of a) and VEGFR2 ( lower row of a) antibodies. (b) Percent of HDAC3 positive tumor cells (left column) was calculated with ImageJ Software. VEGFR2 positive vascules (right column) were counted. Both were then used for statistical analysis. Values were indicated as mean ± SD of three independent experiments. Two-way ANOVA was utilized. Statistical significance was set at P < 0.05. “*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001” are used to denote the significance levels. (c) Protein levels of HDAC3, VEGFR2 and PI3K/AKT cascade of tumor tissues were determined by western blot.